Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 566-569

  Mariné, Marçal ^a   Espada, Raquel ^b   Torrado, Juan ^b   Pastor, F Javier ^a   Guarro, Josep ^a  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amphotericin B; Animal models; Candidiasis; Microspheres

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CANDIDA TROPICALIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; HISTOPATHOLOGY; INVASIVE CANDIDIASIS; KIDNEY PARENCHYMA; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TOXICITY TESTING;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; FEMALE; MALE; MICE; MICROSPHERES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70350381607     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.07.005     Document Type: Article

References (19)

1. Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
2. Hiemenz J.W., and Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22 Suppl. 2 (1996) S133-S144
3. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., and Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 254 (2003) 73-75
4. Torrado JJ, Torrado S, Sánchez-Brunete JA, Bolás F, Dea MA, Rama S, et al. 22-12-2005. Microesferas de anfotericina B. Spanish patent ES2212904B2.
5. Sánchez-Brunete J.A., Dea M.A., Rama S., Bolás F., Alunda J.M., Raposo R., et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 48 (2004) 3246-3252
6. Sánchez-Brunete J.A., Dea M.A., Rama S., Bolás F., Alunda J.M., Torrado-Santiago S., et al. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J Drug Target 13 (2005) 225-233
7. Espada R., Valdespina S., Dea M.A., Molero G., Ballesteros M.P., Bolás F., et al. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. J Antimicrob Chemother 61 (2008) 1125-1131
8. Espada R., Valdespina S., Molero G., Dea M.A., Ballesteros M.P., and Torrado J.J. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Int J Antimicrob Agents 32 (2008) 55-61
9. Pappas P.G., Kauffman C.A., Andes D., Benjamin Jr. D.K., Calandra T.F., Edwards Jr. J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. Document M27-A3. Wayne, PA: CLSI; 2008.
11. Marine M., Serena C., Fernandez-Torres B., Pastor F.J., and Guarro J. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Antimicrob Agents Chemother 49 (2005) 4757-4759
12. Ortoneda M., Capilla J., Pujol I., Pastor F.J., Mayayo E., Fernández-Ballart J., et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 49 (2002) 525-529
13. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
14. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37 (2003) 634-643
15. Rubio M.C., de Ocáriz I.R., Gil J., Benito R., and Rezusta A. Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrob Agents 25 (2005) 264-267
16. Quindós G., Carrillo-Muñoz A.J., Eraso E., Cantón E., and Pemán J. In vitro antifungal activity of voriconazole: new data after the first years of clinical experience. Rev Iberoam Micol 24 (2007) 198-208 [in Spanish]
17. Sóczó G., Kardos G., McNicholas P.M., Balogh E., Gergely L., Varga I., et al. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J Antimicrob Chemother 60 (2007) 1004-1009
18. Johnson E., Espinel-Ingroff A., Szekely A., Hockey H., and Troke P. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 32 (2008) 511-514
19. Spellberg B.J., Filler S.G., and Edwards Jr. J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42 (2006) 244-251